inotersen (Rx)

Brand and Other Names:Tegsedi
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 284mg/1.5mL single-dose prefilled syringe

Hereditary Transthyretin Amyloidosis

Indicated for polyneuropathy of hereditary transthyretin amyloidosis (hATTR-PN) in adults

284 mg SC once weekly; administer on the same day each week

Dosage Modifications

Platelets

  • Do not initiate if <100x 10^9/L
  • If signs or symptoms of thrombocytopenia develop, obtain platelet count as soon as possible, and hold dosing until platelet count is confirmed; recheck platelet count as soon as possible if a platelet measurement is uninterpretable
  • Platelet count ≥100x 10^9/L
    • Monitor weekly
    • Continue to dose weekly
  • Platelet count ≥75 to <100 x 10^9/L
    • Monitor weekly
    • Stop treatment; may resume if platelet count >100
  • Platelet count ≥50 to <75x 10^9/L
    • Monitor twice weekly until 3 successive values >75, then weekly
    • Stop treatment; may resume after 3 successive values >100 and the benefit of inotersen outweighs thrombocytopenia risk
  • Platelet count ≥25 to <50x 10^9/L
    • Monitor twice weekly until 3 successive values >75, then weekly
    • Stop treatment; may resume after 3 successive values >100 and the benefit of inotersen outweighs thrombocytopenia risk
    • Corticosteroids recommended
    • Consider discontinuation of any antiplatelet agents or anticoagulants
  • Platelet count <25x 10^9/L
    • Monitor daily until 2 successive values >25, then twice weekly until 3 successive values >75, then weekly until stable
    • Stop treatment
    • Corticosteroids recommended
    • Consider discontinuation of any antiplatelet agents or anticoagulants

UPCR or eGFR

  • Urine protein to creatinine ratio (UPCR) ≥1000 mg/g or eGFR <45 mL/min/1.73 m²: Hold dosing pending further evaluation
  • Once eGFR ≥45 mL/minute/1.73 m², UPCR <1000 mg/g, or the underlying cause of the decline in renal function is corrected, may resume weekly dosing
  • UPCR ≥2000 mg/g: Perform further evaluation for acute glomerulonephritis, as clinically indicated
  • If acute glomerulonephritis confirmed, permanently discontinue

Renal impairment

  • Mild-to-moderate (eGFR ≥30 to <90 mL/min/1.73 m²): No dose adjustment required
  • Severe or end-stage renal disease: Not studied

Hepatic impairment

  • Mild: No dose adjustment required
  • Moderate-to-severe: Not studied

Dosing Considerations

Laboratory assessment

  • Also see Black Box Warnings
  • Before initiating: Measure platelet count, serum creatinine, eGFR, UPCR, ALT, AST, and total bilirubin, and perform urinalysis
  • After initiating: Monitor platelet count, serum creatinine, eGFR, urinalysis, UPCR, ALT, AST, and total bilirubin during treatment and for 8 weeks after discontinuing
  • Monitor ALT, AST, and total bilirubin q4months
  • Monitor serum creatinine, eGFR, urinalysis, and UPCR q2weeks

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and inotersen

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Injection site reactions (49%)

            Nausea (31%)

            Headache (26%)

            Fatigue (25%)

            Thrombocytopenia (24%)

            Fever (20%)

            Peripheral edema (19%)

            Chills (18%)

            Anemia (17%)

            Vomiting (15%)

            Myalgia (15%)

            Decreased renal function (14%)

            Arrhythmia (13%)

            Arthralgia (13%)

            Presyncope or syncope (13%)

            1-10%

            Decreased appetite (10%)

            Paresthesia (10%)

            Dyspnea (9%)

            Elevated liver function test (9%)

            Orthostasis (8%)

            Influenzalike illness (8%)

            Contusion (7%)

            Bacterial infection (7%)

            Eosinophilia (5%)

            Dry mouth (5%)

            Previous
            Next:

            Warnings

            Black Box Warnings

            Thrombocytopenia

            • Reductions in platelet count may result in sudden and unpredictable thrombocytopenia, which can be life-threatening
            • One clinical trial patient died from intracranial hemorrhage
            • Contraindicated in patients with a platelet count <100x 10^9/L
            • Obtain a platelet count before initiating drug
            • During treatment, monitor platelet counts weekly if values are ≥75x 10^9/L, and more frequently if values are <75x 10^9/L
            • If signs or symptoms of thrombocytopenia develop, obtain a platelet count as soon as possible; hold dosing until platelet count is determined to be interpretable and acceptable by a medical professional
            • Following discontinuation of treatment for any reason, continue to monitor platelet count for 8 weeks, or longer if platelet counts are <100x 10^9/L, to verify that platelet counts remain >75x 10^9/L

            Glomerulonephritis

            • Inotersen can cause glomerulonephritis that may require immunosuppressive treatment and may result in dialysis-dependent renal failure
            • One clinical trial patient who developed glomerulonephritis and did not receive immunosuppressive treatment remained dialysis dependent
            • In clinical trials, cases of glomerulonephritis were accompanied by nephrotic syndrome, which can have manifestations of edema, hypercoagulability with venous or arterial thrombosis, and increased susceptibility to infection
            • Should generally not be initiated in patients with UPCR ≥1000 mg/g
            • Before initiating drug, measure serum creatinine, eGFR, UPCR, and perform urinalysis
            • During treatment, monitor serum creatinine, eGFR, urinalysis, and UPCR q2weeks
            • Do not administer to patients who develop UPCR ≥1000 mg/g or eGFR <45 mL/minute/1.73 m², pending further evaluation of the cause
            • If dose held, may reinitiate weekly dosing once eGFR increases to ≥45 mL/minute/1.73 m², UPCR decreases to <1000 mg/g, or the underlying cause of the decline in renal function is corrected
            • If UPCR ≥2000 mg/g, perform further evaluation for acute glomerulonephritis, as clinically indicated; if confirmed, permanently discontinue inotersen

            REMS program

            • Owing to risks of serious bleeding caused by severe thrombocytopenia and glomerulonephritis, both of which require frequent monitoring, inotersen is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS)

            Contraindications

            Platelet count <100x 10^9/L

            History of acute glomerulonephritis caused by inotersen

            Hypersensitivity

            Cautions

            Causes platelet count reduction that may result in sudden and unpredictable thrombocytopenia that can be life-threatening; monitoring required

            Uninterpretable platelet counts may occur owing to platelet clumping that occurs between antiplatelet antibodies and EDTA; if EDTA-mediated platelet clumping suspected, repeat platelet count using a different anticoagulant (eg, sodium citrate, heparin) in the blood collection tube

            Can cause glomerulonephritis that may result in dialysis-dependent renal failure; monitoring required; treatment for glomerulonephritis is immunosuppressive therapy; avoid use in patients for whom immunosuppressive treatment is not advised

            Prescribers must be certified to prescribe inotersen by enrolling in and completing the REMS training program; patients must enroll in the program and comply with ongoing monitoring requirements

            May cause stroke and cervicocephalic arterial dissection (rare) within 2 days of the first dose; patients may also have symptoms of cytokine release (eg, nausea, vomiting, muscular pain, weakness) and a high-sensitivity C-reactive protein level >100 mg/L during this time

            Vitamin A levels may decrease; supplementation with recommended daily allowance advised; refer to ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occurs (eg, night blindness)

            Inflammatory and immune effects

            • May cause inflammatory and immune changes, including immune thrombocytopenia, glomerulonephritis, or rarely, antineutrophil cytoplasmic autoantibody (ANCA)-positive systemic vasculitis
            • One patient developed gait changes that progressed over 6 months to paraparesis, in the absence of radiologic evidence of spinal cord compression
            • Another patient developed progressive lumbar pain, weight loss, headache, vomiting, and impaired speech 7 months after starting inotersen; CSF analysis findings included elevated protein, lymphocyte-predominant pleocytosis, and testing that was negative for infection; recovery occurred after empiric therapy (ie, high-dose steroids, antibiotics) and the patient resumed inotersen without recurrence of symptoms
            • The liver accumulates antisense oligonucleotides; monitor ALT, AST, and total bilirubin
            • Hypersensitivity may occur; discontinue treatment and do not reinitiate

            Drug interaction overview

            • Owing to thrombocytopenia risk, caution if inotersen is coadministered with antiplatelets or anticoagulants
            • Caution if coadministered with other drugs that may impair renal function
            Previous
            Next:

            Pregnancy

            Pregnancy

            There are no available data regarding use in pregnant women

            Inotersen treatment leads to a decrease in serum vitamin A levels, and vitamin A supplementation is advised for patients taking inotersen; vitamin A is essential for normal embryofetal development; however, excessive levels of vitamin A are associated with adverse developmental effects

            Effects on the fetus of maternal serum transthyretin (TTR) reduction caused by inotersen and vitamin A supplementation are unknown

            Animal studies

            • In animal studies, SC administration of inotersen to pregnant rabbits resulted in premature delivery and reduced fetal body weight

            Lactation

            Unknown if distributed in human milk

            The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Antisense oligonucleotide that causes degradation of mutant and wild-type transthyretin (TTR) mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues

            In patients with ATTR, TTR builds up as fibrils in tissues (eg, peripheral nerves, heart, GI system, eyes, kidneys, CNS, thyroid, bone marrow); the presence of TTR fibrils interferes with the normal functions of these tissues

            Absorption

            Peak plasma time: 2-4 hr

            Peak plasma concentration: 6.39 mcg/mL

            Trough plasma concentration: 0.034 mcg/mL

            AUC: 90 mcg·hr/mL

            Distribution

            Protein bound: >94%

            Vd: 293 L

            Metabolism

            Metabolized by nucleases to nucleotides of various lengths

            Elimination

            Half-life: 32.3 days

            Total body clearance: 3.18 L/hr

            Excretion: Urine <1% (unchanged)

            Previous
            Next:

            Administration

            SC Preparation

            Remove from refrigerator at least 30 minutes before administration to reach room temperature; do not use other warming methods (eg, water bath, microwave)

            Inspect visually for particulate matter and discoloration before administration; solution should appear colorless to pale yellow

            SC Administration

            For SC injection only

            Administer first injection by the patient or caregiver under the guidance of an appropriately qualified healthcare professional; train patients and/or caregivers SC administration

            Injection SC in abdomen, upper thigh region, or outer area of upper arm; injection in upper arm should be administered by person other than the patient

            Rotate injection sites

            Avoid injection at the waistline and other sites where pressure or rubbing from clothing may occur

            Do not inject into areas of skin disease or injury; also avoid tattoos and scars

            Use each syringe only once

            Missed dose

            • Instruct patient to take missed dose as soon as possible, unless next scheduled dose is within 2 days
            • If next dose within 2 days, direct patient to skip the missed dose and take the next scheduled dose on the scheduled day

            Storage

            Store refrigerated at 2-8°C (36-46°F) in the original container

            Do not freeze

            Can be kept at room temperature (not to exceed 30°C [86°F]) in the original container for up to 6 weeks; if not used within the 6 weeks, discard

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.